Trial Profile
A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and Activated PI3K Pathway
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary)
- Indications Glioblastoma; Glioma
- Focus Pharmacokinetics; Therapeutic Use
- 05 Mar 2019 Status changed from active, no longer recruiting to completed.
- 07 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
- 04 Feb 2019 Results published in the Journal of Clinical Oncology